)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Egetis Therapeutics
Egetis Therapeutics (EGTX) investor relations material
Egetis Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
FDA approved EMCITATE on Sep 28 as the first and only U.S. treatment for peripheral thyrotoxicosis in patients with MCT8 deficiency; U.S. launch began Oct 27.
Q3 revenue rose 24% YoY at CER to MSEK 21.5, while the quarterly loss widened to MSEK 147.0.
A Nov 4 agreement to sell the FDA-granted PRV for USD 190M is expected to provide a substantial non-dilutive cash contribution; former RTTI owners are entitled to ~50% of net proceeds.
Financial highlights
Q3 revenue was MSEK 21.5 vs. 17.4, up 24% YoY at CER; Jan-Sep revenue was MSEK 52.3 vs. 44.6, up 17% at CER.
Q3 operating loss was MSEK 135.0 vs. 76.5; Jan-Sep operating loss was MSEK 337.2 vs. 219.6.
Net loss was MSEK 147.0 in Q3 vs. 82.4 and MSEK 350.4 for Jan-Sep vs. 222.8; EPS was SEK -0.3 and -0.8, respectively.
Q3 operating expenses rose to MSEK 136.9 from 80.0, mainly on U.S. launch preparation and operational build-out; Jan-Sep marketing and sales costs reached MSEK 123.6 vs. 66.1.
Gross profit was MSEK 1.9 in Q3 vs. 3.5 and MSEK 5.2 for Jan-Sep vs. 8.2; COGS included a one-time MSEK 4.0 EMC approval milestone in Q3.
Outlook and guidance
2026 priorities: execute the U.S. EMCITATE launch, optimize European pricing and reimbursement while continuing launch, and finalize tiratricol’s RTH-beta development plan.
Japan NDA submission for EMCITATE is expected in 2027; preparations are ongoing using data from the global clinical program.
Regulatory interactions and development planning for tiratricol in RTH-beta are in preparation; the indication remains investigational.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Egetis Therapeutics
- Existing clinical data support the planned European MAA for Emcitate.EGTX
Status Update - FDA approved EMCITATE as the first U.S. treatment for MCT8 deficiency, launching in 8–10 weeks.EGTXFDA announcement
- Upcoming U.S. approval and global expansion set the stage for growth in rare disease therapies.EGTXMorgan Stanley 24th Annual Global Healthcare Conference
- Strong clinical data, U.S. launch focus, and pipeline expansion drive rare disease growth.EGTX12th Annual Cantor Fitzgerald Global Healthcare Conference
- Emcitate is set for US launch in 2026 after EU approval, addressing a critical unmet need in MCT8 deficiency.EGTXCorporate presentation
- FDA review progresses, European sales up 23%, and cash position reaches SEK 378.4 million.EGTXQ2 2026
- Emcitate delivers first-in-class treatment for MCT8 deficiency, driving growth and global expansion.EGTXCorporate presentation
- Emcitate showed strong T3 reduction and safety, but no neurocognitive benefit in young MCT8 patients.EGTXStudy Result
- Emcitate receives EU approval as first MCT8 deficiency therapy; Germany launch in Q2 2025.EGTXQ4 2024
Next Egetis Therapeutics earnings date
Stifel 2026 Healthcare Conference12 Nov, 2026
Egetis Therapeutics
Next Egetis Therapeutics earnings date
Stifel 2026 Healthcare Conference12 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Egetis Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of treatments for rare and severe diseases. Its portfolio includes late-stage product candidates targeting unmet medical needs. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq Stockholm.